Darlene Dobkowski, Managing Editor for CURE® magazine, has been with the team since October 2020 and has covered health care in other specialties before joining MJH Life Sciences. She graduated from Emerson College with a Master’s degree in print and multimedia journalism. In her free time, she enjoys buying stuff she doesn’t need from flea markets, taking her dog everywhere and scoffing at decaf.
Savoring Every Ounce of Life While Undergoing Treatment for Skin Cancer
January 14th 2021In this episode of the “CURE Talks Cancer” podcast, we spoke with someone who has undergone 41 surgeries and physically debilitating treatments during his more than 15-year journey with several cases of skin cancer. We discussed his cancer journey, and why, as he starts a new treatment after his most prior therapy failed, he’s focused on quality rather than quantity of life.
Read More
Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma
January 13th 2021Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.
Read More
Patients older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.
Read More
Bristol-Myers Squibb Pulls Small Cell Lung Cancer Indication for Opdivo
January 4th 2021The company has withdrawn the small cell lung cancer indication for Opdivo (nivolumab) based on discussions with the FDA, particularly focused on post-market studies that missed their primary endpoints of overall survival.
Read More
COVID-19 Pandemic May Impact Clinical Trial Enrollment Due to Increased Exposure to the Virus
January 4th 2021In participants who reported that the pandemic negatively impacted their decision to enroll in a clinical trial, some of the most common reasons included exposure to the virus and limited access to care.
Read More
Communication With the Treatment Team, Self-Advocacy Play Important Roles in Small Cell Lung Cancer
January 2nd 2021In an interview with CURE®, Dr. Wade T. Iams discussed small cell lung cancer, a subtype of lung cancer that starts from neuroendocrine cells in the lung, how different stages are treated and the potential benefits of having a treatment team to communicate with every step of the way.
Read More
FDA Lifts Hold on Trial Assessing CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma
December 30th 2020The Food and Drug Administration lifted a clinical hold on the MELANI-01 trial, evaluating UCARTCS1A, a CAR T-cell product in patients with relapsed or refractory multiple myeloma.
Read More
Clinical Trials on Smoldering Myeloma May Open Doors to More Precision Medicine
December 29th 2020In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.
Read More
FDA Approves Tagrisso as Adjuvant Therapy for Non-Small Cell Lung Cancer After Tumor Resection
December 18th 2020This approval allows Tagrisso to be used after tumor resection in non-small cell lung cancer patients with tumors that have certain epidermal growth factor receptor mutations or deletions.
Read More
FDA Approves Xpovio for Use with Velcade and Dexamethasone in Multiple Myeloma
December 18th 2020This treatment regimen of Xpovio with Velcade, approved for patients with multiple myeloma previously treated with at least one therapy, provides another option for patients with multiple myeloma to potentially close the treatment gap.
Read More
Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer
December 12th 2020Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.
Read More
Dietary Changes to Reduce Diabetes Risk May Also Increase Survival for Breast Cancer
December 10th 2020Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.
Read More
The combination of ublituximab and umbralisib, two novel compounds, was able to safely prolong progression-free survival with low rates of toxicities in patients with chronic lymphocytic leukemia compared with standard of care chemoimmunotherapy regardless of prior treatment.
Read More
The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
Read More